Dividend Win Wednesday: Device Deals and 26% Drawdowns Hiding 38% Upside

This Week's Setup

The dividend screen rotates from resource and steel names at highs to healthcare and financials sitting 15–26% below 52-week peaks. Medtronic, Becton Dickinson, and Biogen own Pixie Ranks 1 through 3, each posting FCF yields above 5% and earnings yields that clear 3.8%.

Greed at 61 keeps the S&P 500 CAPE near 39, but the top 8 here trade at a median normalized P/E under 22, with four names holding net debt below 2× EBITDA. Half the list showed insider purchases in the past 30 days, and five draw 20%+ analyst upside.

AstraZeneca and Amgen combine 150-basis-point ROIC with double-digit revenue growth. Medtronic's $650 million SPR Therapeutics acquisition puts chronic pain in its device portfolio the same week the stock sits 26% off highs and offers a 3.6% dividend.

Quick Scan

The 8 Names

1. Medtronic plc (MDT)

Dividend yield: 3.6% | Payout ratio: 78% | 52w drawdown: -26.3%

Medtronic holds Pixie Rank 1 with a 5.2% FCF yield, 7.4% ROIC, and 78¢-per-dollar payout cover. The price sits 26% below the 52-week peak while earnings yield clears 4.6%, 70 basis points wider than the flat 10-year Treasury rate over the measurement window. Analysts see 38% upside to $108, the widest gap in the top eight.

The company announced intent to acquire SPR Therapeutics for $650 million on May 16, expanding into chronic pain with a non-opioid peripheral nerve stimulation platform. Craig Arnold, John Groetelaars, and Gregory Lewis each filed Form 4 dispositions on April 29, totaling 8,051 net shares sold; the stock has been flat on a trailing one-year trend.

Net debt sits at 2.1× EBITDA and the 78% payout ratio leaves 22 cents of FCF per dividend dollar. Interest coverage at 9× gives room, but revenue growth at 3.6% year-over-year trails the device peer set and leaves the thesis riding on margin expansion and the SPR integration.

2. Becton, Dickinson and Company (BDX)

Dividend yield: 2.9% | Payout ratio: 69% | 52w drawdown: -21.4%

BDX posts a 6.6% FCF yield and 8.2% revenue growth at a 21% drawdown from the 52-week high, the second-deepest entry zone in the top five. The 3.9% earnings yield and net debt at 2.7× EBITDA frame a leveraged setup, but interest coverage at 4× and gross margin at 45% support the distribution.

Carrie Byington, Vitor Roque, and Robert Huffines each filed Form 4 buys on May 8, adding 111,335 net shares and $5.55 million in value over the past six months. The company appointed Peter Menziuso as EVP and President of BD Interventional, and Barclays lifted its target following solid Q2 performance.

The 69% payout ratio leaves 31 cents of cover per dividend dollar, and the normalized 10-year P/E shows negative 76 basis points of yield spread. The stock has trended up only 0.07% over the trailing year, suggesting the market is waiting for proof that revenue growth sustains above 8%.

3. AstraZeneca PLC (AZN)

Dividend yield: 1.7% | Payout ratio: 48% | 52w drawdown: -12.9%

AstraZeneca combines a 14.8% ROIC with 8.6% revenue growth and a 3.0% FCF yield, the lowest absolute yield in the top eight but paired with a 48% payout ratio that leaves 52 cents of cover per dividend dollar. The price sits 13% below the 52-week peak while analysts model 21% upside to $224.

Mani Sharma filed a May 8 Form 4 transaction for $5 million in equity, and the company sits at the center of the GLP-1 obesity pill race alongside Novo Nordisk and Eli Lilly. Big Pharma R&D specialization is the strategic pivot theme across sell-side commentary, and AstraZeneca's 82% gross margin gives room to fund that shift.

The 1.7% dividend yield is the lowest in the screen, and five-year dividend growth has been negative 5.1%. Net debt at 1.3× EBITDA is manageable, but the 28 P/E and 6× price-to-book suggest the market already prices in oncology and metabolic pipeline optionality.

4. Amgen Inc. (AMGN)

Dividend yield: 3.0% | Payout ratio: 71% | 52w drawdown: -15.2%

Amgen posts a 17.2% ROIC, 10% revenue growth, and 4.5% FCF yield at a 15% drawdown, the deepest pullback among the top four. The 4.3% earnings yield and 71% payout ratio leave 29 cents of cover, and the stock has trended up 0.12% over the past year while sitting 15% off peak.

Derek Miller, Peter Griffith, and Nancy Grygiel filed May 2026 Form 4 transactions totaling 261,689 net shares and $6.44 million in value over six months, with 35.5% of insider transactions as buys. Peter Griffith announced his retirement as CFO, with Thomas Dittrich named successor, and Argus adjusted the price target to $375 from $400 while maintaining Buy.

Net debt sits at 2.7× EBITDA, and the 23 P/E paired with a 19.5 price-to-book flags a balance-sheet-light model leaning on intangible assets. Five-year dividend growth has been negative 6.5%, and 2.4% short interest is the highest in the pharma cohort here.

5. Bank of America Corporation (BAC)

Dividend yield: 2.2% | Payout ratio: 26% | 52w drawdown: -11.3%

Bank of America owns the lowest P/E in the screen at 12.7 and the highest earnings yield at 7.9%, 490 basis points wider than the normalized 10-year equivalent. The 2.2% dividend costs only 26% of FCF, leaving 74 cents of cover, and the stock sits 11% below the 52-week high while analysts model 23% upside to $63.

Pierre de Weck, Jose Almeida, and Denise Ramos filed Form 4 transactions on April 24 and May 6, adding 2.9 million net shares over six months. The bank reached a $2.25 million ATM fee class action settlement, and Zacks linked the 6.7% shareholder yield to Gen Z crypto ETF exposure habits.

Revenue growth at 6.8% lags the healthcare names, and the 0.0% short interest suggests no crowd expecting downside. The thesis here is rate-sensitive spread income meeting a cyclical earnings trough; if the 10-year stays flat and deposits stabilize, the 8% earnings yield reverts to multiple expansion rather than distribution growth.